Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | HTR6 | P50406 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | HTR2C | P28335 | 6/20 | 0.46 |
| ▸ | HTR7 | P34969 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286968 | 0.77 | HTR7 (0.49) | MAPTHTR6HTR2AHTR2CHTR7 | |
| SCHEMBL6287512 | 0.74 | KMT2A (0.45) | LMNAGAAMEN1CYP2D6KMT2A | |
| SCHEMBL7529516 | 0.74 | HTR6 (0.45) | MAPTHTR6HTR2AHTR2CHTR7 | |
| SCHEMBL6286641 | 0.74 | MAPT (0.46) | MAPTHTR6HTR2AHTR2CHTR7 | |
| SCHEMBL6290202 | 0.72 | HTR6 (0.42) | MAPTHTR6ALDH1A1HPGDLMNA | |
| SCHEMBL7531036 | 0.71 | HTR6 (0.43) | MAPTHTR6ALDH1A1HPGDLMNA | |
| SCHEMBL2119402 | 0.65 | ALDH1A1 (0.67) | MAPTALDH1A1HPGDHIF1AEPAS1 | |
| SCHEMBL8485302 | 0.65 | MAPK1 (0.53) | MAPTHTR6HTR2AHTR2CALDH1A1 | |
| SCHEMBL10797349 | 0.64 | HTR6 (0.51) | HTR6HTR7KMT2A | |
| SCHEMBL21456816 | 0.63 | KMT2A (0.43) | HTR6ALDH1A1MEN1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872716-B2 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | SEPRACOR, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040235832-A1 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | WU XINHE (US) | 2004-11-25 | — | — | US | disclosed |
| US-6703383-B2 | HETEROCYCLIC COMPOUNDS COMPRISING A SULFONAMIDE GROUP TO TREAT DISEASES SUCH AS PSYCHOLOGICAL DISORDERS CAUSED BY ONE OR MORE PROTEIN-G COUPLED RECEPTORS OR LIGAND -GATED ION CHANNELS | SEPRACOR, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20020065265-A1 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | SEPRACOR INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002022579-A2 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065265-A1 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | TRPV1, CNR2, TRPM5 | MAPT 2966/4885HTR6 231/4885HTR2A 64/4885 |
| US-20040235832-A1 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | TRPV1, CNR2, TRPM5 | MAPT 2966/4885HTR6 231/4885HTR2A 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.